Upsher-Smith Laboratories has received approval from the Food and Drugs Administration (FDA) for Bumetanide Tablets, the generic version of Bumex.
Bumetanide, a loop diuretic, is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including nephrotic syndrome. It works by inhibiting sodium reabsorption in the ascending limb of the loop of Henle. Reabsorption of chloride in the ascending limb is also blocked by bumetanide and potassium excretion is increased by bumetanide in a dose-related manner.
Bumetanide Tablets will be available as 0.5mg, 1mg, and 2mg strengths in 100-count bottles. The Company stated that they are prepared to begin shipping product to wholesalers in early February, 2018.
For more information call (800) 654-2299 or visit Upsher-Smith.com.